scholarly article | Q13442814 |
P50 | author | Giuseppe Giaccone | Q37829946 |
Karen L. Reckamp | Q46041139 | ||
Sean Khozin | Q48504033 | ||
Eva Szabo | Q69483163 | ||
Everett E Vokes | Q73567428 | ||
Jane B Trepel | Q111692206 | ||
P2093 | author name string | R Salgia | |
M J Lee | |||
M Raffeld | |||
C A Carter | |||
A Thomas | |||
S Lee | |||
S M Steinberg | |||
L Xi | |||
L A Doyle | |||
D Gandara | |||
A Rajan | |||
Y Tomita | |||
S Koehler | |||
C Keen | |||
B Gitlitz | |||
U Guha | |||
C Brzezniak | |||
P2860 | cites work | KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib | Q21563446 |
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors | Q24294914 | ||
Somatic mutations affect key pathways in lung adenocarcinoma | Q24648102 | ||
Cancer statistics, 2014 | Q27861018 | ||
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives | Q28289431 | ||
Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation | Q28609161 | ||
How MAP kinases are regulated | Q28609360 | ||
Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
Immunogenic cell death in cancer therapy | Q29620118 | ||
Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines | Q34129528 | ||
RET, ROS1 and ALK fusions in lung cancer | Q34253845 | ||
MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro | Q34615021 | ||
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial | Q35168763 | ||
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer | Q37274280 | ||
New targets in advanced NSCLC: EML4-ALK. | Q37862973 | ||
The secret ally: immunostimulation by anticancer drugs | Q37981038 | ||
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 | ||
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors | Q39355055 | ||
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens | Q42673662 | ||
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer | Q43152544 | ||
Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations | Q43179196 | ||
Imbalance in the Th17/Treg and cytokine environment in peripheral blood of patients with adenocarcinoma and squamous cell carcinoma | Q45152931 | ||
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial | Q46542092 | ||
K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. | Q52914148 | ||
Chemotherapy for non-small cell lung cancer | Q71791935 | ||
P433 | issue | 4 | |
P921 | main subject | erlotinib | Q418369 |
P304 | page(s) | 693-699 | |
P577 | publication date | 2016-01-22 | |
P1433 | published in | Annals of Oncology | Q326122 |
P1476 | title | Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer | |
P478 | volume | 27 |
Q55339149 | A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC. |
Q42363767 | A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors |
Q55259943 | A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. |
Q39220897 | Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. |
Q50345931 | Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes |
Q47145152 | Correlation between MEK signature and Ras gene alteration in advanced gastric cancer |
Q42700668 | Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials |
Q39538184 | Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials |
Q39145987 | Functional exploration of colorectal cancer genomes using Drosophila |
Q48877738 | Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). |
Q38899873 | Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer |
Q90326601 | Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials |
Q49787333 | Implications of KRAS mutations in acquired resistance to treatment in NSCLC. |
Q37743107 | Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer |
Q37709450 | KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies |
Q49887897 | KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target |
Q42332672 | Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design |
Q93018169 | MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells |
Q47318847 | MEK inhibitors under development for treatment of non-small-cell lung cancer |
Q60915896 | Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target |
Q96302844 | RAS-targeted therapies: is the undruggable drugged? |
Q38792704 | Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial |
Q38663069 | Selumetinib for the treatment of non-small cell lung cancer |
Q38836927 | Selumetinib in the treatment of non-small-cell lung cancer |
Q47671139 | Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. |
Q64374979 | The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer |
Q37477372 | The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinosta |
Q39045958 | The role of the immune system in neurofibromatosis type 1-associated nervous system tumors |
Search more.